Cardiac Mapping Market - By Product, By Type, By Indication, By End Use - Global Forecast, 2025 - 2034

Cardiac Mapping Market Size

The global cardiac mapping market was valued at USD 3.4 billion in 2024. The market is expected to reach from USD 4.1 billion in 2025 to USD 10.9 billion in 2034, growing at a CAGR of 11.3% from 2025 to 2034. The high market growth is attributed to the growing prevalence of cardiac arrhythmias, technological advancements in mapping systems, increasing demand for minimally invasive procedures, surging investments and funding in electrophysiology, and expanding healthcare infrastructure in emerging markets, among other contributing factors.

Cardiac mapping is an advanced technique for the diagnosis of the heart's electrical activities for rhythms such as arrhythmias. It involves the construction of the heart with respect to its signals using catheters with electrodes. This enables and assists healthcare providers in addressing the underlying cause of dysrhythmias and aids in the management processes such as catheter ablation. It is commonly used in patients with atrial fibrillation, ventricular tachycardia, and other complex arrhythmias. Leading companies in the cardiac mapping market are Johnson & Johnson, Abbott Laboratories, Boston Scientific, and Medtronic. These companies dominate the industry owing to their competitive strategies in new product development, international market reach, and substantial research spending.
 

The market has increased from USD 1.7 billion in 2021 and reached USD 2.5 billion in 2023, with the historic growth rate of 9.7%. The market growth was driven by the growing elderly population, which has been at a higher risk of cardiovascular diseases, thereby increasing the demand for cardiac mapping systems. As reported by World Health Organization (WHO), the global population aged 60 years is expected to grow from 1 billion in 2021 to 2.1 billion by 2050, providing a greater boost to the markets.
 

The global health burden of atrial fibrillation, atrial flutter, and complex arrhythmia increases the need for effective diagnostic methods. For example, the American Heart Association, Inc. reported that AFib affects about 5 million people within the U.S. alone, and that number is expected to surge past 12 million by 2030. Cardiac mapping is used to find and precisely locate arrhythmic foci, which enables effective ablation therapy.
 

In addition, both government and private funding for cardiology and electrophysiology continue to increase. The National Institutes of Health (NIH) funded cardiovascular research projects with USD 2.8 billion in 2023, which was increased from 2.5 billion in 2021. Also, the European Union Horizon Europe program set aside approximately USD 410 million from 2021 to 2024 for designated initiatives in cardiac research.
 

These grants enables advancement in development of training programs for healthcare professionals and mapping technology. Strategic acquisitions and collaborations to improve cardiac mapping systems led major players in this market to invest roughly USD 1.2 billion in 2023. Such investments further the development of the global market for cardiac mapping.
 

Cardiac Mapping Market Trends

The market is witnessing significant growth driven by the rise of hybrid & 3D mapping systems, artificial intelligence (AI) in healthcare, machine learning, and big data integration, growing demand for non-invasive & remote mapping technologies, shift toward patient-centric personalized care, and expanding applications beyond arrhythmia, among other factors are boosting the industry growth.
 

• The market shows higher adoption of hybrid systems that merge magnetic with impedance-based mapping which provide incorporation of multifaceted anatomical and electrical data pertaining to the heart. The FDA reported a 28% increase in the approval rate for cardiac mapping systems from 2021 to 2023.
   
• The innovation of 3D electro-anatomical mapping technologies such as CARTO 3 and EnSite X increases accuracy and procedural guidance in cardiac procedures. The European Heart Rhythm Association reported the utilization of 3D mapping systems in cardiac procedures increased from 68% in 2021 to 82% in 2023, with 45% of all installations in 2023 being hybrid systems.
   
• Additionally, the non-contact methods (MRI, optical, and ultrasound) are gaining popularity with mapping due to their less invasive nature and higher patient comfort levels. Also, telemedicine as well as remote patient monitoring is broadening the scope of mapping beyond the traditional EP labs.
   
• In North America and Europe, favorable reimbursement and regulatory approval policies facilitate the commercialization of sophisticated medical systems. Notably, there has been an upward trend in medical device approvals, with the U.S. FDA approving 103 devices in 2021 and 115 in 2022. Meanwhile, emerging markets such as China are expected to increase healthcare spending, driven by initiatives like the planned USD 89 billion investment in healthcare infrastructure from 2021 to 2024.
   
• Furthermore, global market leaders such as Abbott, Johnson & Johnson, and Boston Scientific are increasingly pursuing mergers and acquisitions to enhance innovation and diversify their cardiac mapping portfolios.
   
• In May 2023, Abbott announced a global collaboration to integrate its EnSite X EP System with Stereotaxis’ Robotic Magnetic Navigation (RMN) systems. This partnership not only enables Abbott to enhance real-time cardiac mapping but also leverages the precision of robotic catheter navigation improving procedural accuracy, increasing workflow efficiency, and expanding access to advanced arrhythmia treatments.
   

Cardiac Mapping Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The global market was valued at USD 1.7 billion in 2021. The market size reached USD 2.5 billion in 2023, from USD 2 billion in 2022.
 

Based on the product, the market is segmented into mapping catheters and mapping systems. The mapping catheters segment has asserted its dominance in the market by securing a significant market share of 74% in 2024 owing to the increasing incidence of atrial fibrillation and complex arrhythmias, surging demand for minimally invasive electrophysiology procedures, and continous advancements in high-density and multi-electrode catheters. The segment is expected to exceed USD 7.9 billion by 2034, growing at a CAGR of 11.1% during the forecast period. On the other hand, mapping systems segment is expected to grow with a CAGR of 11.8%. The growth of this segment can be attributed to the rising global burden of cardiac arrhythmia, particularly atrial fibrillation and the increasing demand for precision-guided ablation procedures.
 

• The mapping catheters segment continues to dominate the cardiac mapping market with its strong support coming from high-density mapping catheters that are preferred due to their increasing spatial and electrical resolution. These catheters are capable of capturing thousands of data points in a very short span of time, which makes the creation of highly detailed electroanatomical maps possible. This demand is increasing to support complex arrhythmia ablation procedures, specifically for atrial fibrillation (AF) and ventricular tachycardia (VT).
   
• The mapping catheters are meant to be used with 3D electroanatomical mapping systems like CARTO (J&J) and EnSite (Abbott). Their co-operation enhances the visualization of the cardiac structures and pathways and thus helps improve the outcomes of the procedures while boosting the physician’s confidence. As per the FDA, the number of approved cardiac mapping systems increased by 23% from 2021 to 2023.
   
• Further, the use of these catheters is currently on the rise in electrophysiology procedures that are hybrid in nature, including epicardial access and surgical ablations. Their role in managing complex persistent atrial fibrillation (AF) and non-paroxysmal ventricular tachycardia (VT) is also expanding. With the aid of these advanced catheters, visualization of numerous chambers, conduction blocks, and scar tissue is possible further ensuring optimal procedural planning that maintains a competitive edge in cardiac mapping.
   
• The mapping systems segment is projected to experience the fastest growth at a CAGR of 11.8% during the forecast period. This segment appears promising due to the global burden of cardiac arrhythmias, especially atrial fibrillation, along with the increasing need for accuracy in guidied ablation oncology procedures. The improvement of 3D electro-anatomical mapping, real-time visualization, and combination with ablation technologies is improving clinical results, solidifying the preference for these systems in electrophysiology labs.
   
• Moreover, advancing AI-powered mapping systems, emerging markets with expanding healthcare systems, and focus on minimally invasive techniques are likely to bring significant new use. With the coming of additional regulatory approvals and reimbursement policies, the next decade looks attractive for advanced mapping systems.
   

Based on type, the cardiac mapping market is segmented as contact cardiac mapping and non-contact cardiac mapping. The contact cardiac mapping segment dominated the market in 2024 accounting for USD 3 billion and is anticipated to grow at a CAGR of 11.6% during the forecast period.
 

• Contact mapping allows one to observe intracardiac electrical activity with the highest precision possible. With catheter-tissue interfaces maintained, these systems provide accurate activation and voltage maps crucial for diagnosing complex pathological arrhythmias. Their clarity in signals surpasses other systems and therefore is preferred in clinical practice.
   
• Additionally, automatic arrhythmia and electroanatomical mapping systems aid in successful catheter ablation by aiding in spatial and temporal detail for arrhythmogenic site detection. They help doctors find conduction gaps and reentrant circuits, which lead to optimal chronic ablation success. As reported by CMS, there was an increase of 12.3% in the number of catheter ablation procedures from years 2021 to 2023, and an 85% success rate of catheter ablation procedures using contact mapping systems.
   
• The FDA reported that the adoption of contact mapping in cardiac centers grew from 68% in 2021 to 78% in 2023, reflecting an increased focus on procedural outcomes. Furthermore, the American Heart Association estimates that by 2024, over 90% of cardiac centers in the U.S. will integrate contact mapping systems into their ablation workflows.
   
• The non-contact cardiac mapping segment is expected to see the significant growth over the forecast period. Non-contact mapping has the capability to record electrical activity from a whole cardiac chamber without catheter-tissue contact. This enhances the process of mapping complicated arrhythmias such as atrial fibrillation or ventricular tachycardia. Clinical interest is enhanced by the visualization of extensive electrical activation over shorter periods of time.
   
• Further, these can record and assess arrhythmic activity even during ephemeral or dynamic episodes. Thus, they are suitable for patients who suffer from non-sustained arrhythmias or in situations where it is challenging to provoke arrhythmia. Their ability to analyze transient signals quickly enhances their clinical utility, thus driving the growth of this segment in the market.
   

Based on indication, the cardiac mapping market is segmented as atrial fibrillation, atrial flutter, ventricular tachycardia, and other indications. The atrial fibrillation segment dominated the market in 2024 accounting for USD 1.4 billion and is anticipated to grow at a CAGR of 11.8% during the forecast period.
 

• The segment’s growth is driven by the rising global prevalence of atrial fibrillation, increasing adoption of catheter ablation for AF treatment, growing demand for accurate pulmonary vein isolation (PVI), and advancements in mapping for persistent and complex AF.
   
• Atrial fibrillation is a common sustained arrhythmia that affects millions, especially elderly individuals. The incidence of atrial fibrillation is projected to increase due to aging populations with new cardiovascular risk elements such as hypertension and obesity. The condition affects both genders, although men tend to get it more frequently, and women usually experience worse symptoms and a higher likelihood of stroke. This stimulates the market for advanced diagnostic products such as cardiac mapping systems.
   
• In addition, catheter ablation acts as the primary or secondary intervention for atrial fibrillation patients, especially in cases where they are noncompliant with available therapies. The American Heart Association cited that in 2022, there were an estimated 175,000 catheter ablation procedures performed within the U.S., which marked a 15% increase from 2021. These procedures are performed based on the cardiac mapping contours arrhythmia and its triggers spatial roots.
   
• The atrial flutter segment holds the second position in the indication segment and is anticipated to grow over the forecast period. While it is less prevalent than atrial fibrillation, improving ECG interpretation techniques, monitoring through wearables, and screening have led to increased diagnosis of atrial flutter. The rising awareness is also driving an increase in referrals for electrophysiological evaluation and mapping. With growing diagnosis comes growing need for systems that map out the anatomy and guide therapeutic intervention.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the cardiac mapping market is classified into hospitals, EP labs, and other end users. The hospitals segment dominated the market with a revenue share of 60.5% in 2024 owing to the high patient volume for electrophysiology procedures, access to advanced infrastructure and skilled personnel, and favorable reimbursement for in-hospital procedures, among others factors.
 

• The top two end use segments account for over 90% of the total market value, with hospitals as the largest segment. Large hospitals and academic medical centers have shown increasing adoption of advanced cardiac mapping systems like CARTO, EnSite, and Rhythmia. These systems allow high-precision electroanatomical visualization essential for the optimal management of complex arrhythmias. The high-volume centers are prompt to invest in this technology to enhance patient satisfaction.
   
• Cardiac mapping is increasingly becoming important in steering catheter ablation as a result of the ongoing focus by hospitals on providing more minimally invasive procedures. These technologies enable patients to have shorter stays in the hospital, quick recovery periods, and fewer complications. It improves the healthcare experience, since it is patient-focused and aids the healthcare system in delivering value for money.
   
• In addition, hospitals are employing mapping systems for scheduled ablations as well as for urgent inpatient cases such as unstable ventricular tachycardia (VT) or symptomatic atrial fibrillation (AF). Timely intervention facilitated by rapid mapping diminishes the intervention fatigue increase from readmissions and ameliorates care quality. This is observed more frequently in stroke centers and cardiac ICUs which drives the growth of the segment.
   

Looking for region specific data?

Download Free PDF

North America dominated the global cardiac mapping market with the highest market share of 52% in 2024.
 

• The U.S. market was valued at USD 862.1 million and USD 982.1 million in 2021 and 2022, respectively. The market size reached USD 1.7 billion in 2024, growing from USD 1.2 billion in 2023 and is anticipated to grow at a CAGR of 10.6% between 2025 and 2034.
   
• North America, particularly the U.S., has one of the highest rates of atrial fibrillation, atrial flutter, and ventricular arrhythmias globally. As reported by the CDC, about 12.1 million people in the U.S. are expected to have atrial fibrillation in 2023, increasing this figure to 12.9 million in 2024.
   
• Similarly, the American Heart Association reported that 34.2% of adults aged 65 and older were diagnosed with hypertension in 2022, and the obesity rates stood at 41.9% in 2021. These continue to increase the need for the implementation of cardiac mapping technologies in the region.
   
• Additionally, the region is home to a developed healthcare system which includes EP labs and cutting edge technology. Tertiary care hospitals, academic institutions, and cardiac centers undertake complex ablation procedures utilizing state-of-the-art mapping systems. There is a foundation for rapid adoption and stable procedure volumes within this infrastructure.
   
• Moreover, U.S. has developed policies for reimbursement concerning cardiac ablation and electrophysiology procedures. In 2023, CMS announced a 4.5% increase in reimbursement for outpatient hospital services related to cardiac ablation surgeries.
   
• The FDA approval processes aids in quicker innovation in the market, as there have been 12 new cardiac mapping systems receiving FDA clearance between 2021-2023. As of January 2024, the CMS has expanded the coverage of cardiac ablation procedures which will now cover more diagnostic categories with now more patients being able to access these treatment options. These factors enable healthcare practitioners to integrate modern advanced mapping systems.
   

Europe cardiac mapping market accounted for USD 943.5 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Healthcare systems across Europe are increasing investments in early diagnosis and management of cardiovascular diseases. According to the European Society of Cardiology (ESC), healthcare spending on cardiovascular disease prevention increased by 23% between 2021 and 2023.
   
• The adoption of remote ECG telemetry devices, ECG monitors worn on the body, and tele-cardiology services facilitate the diagnosis of rhythmic disorders far ahead of when they would have been detected. There was a 45% increase in the use of remote monitoring in cardiology in 2022, as reported by the European Heart Rhythm Association.
   
• This emphasis on preventive care drives the adoption of cardiac mapping systems, as evidenced by the European Union's USD 2.5 billion allocation for cardiovascular healthcare technology modernization in 2023-2024.
   
• ESC (European Society of Cardiology) has also recommend the use of ablation therapy for atrial fibrillation and atrial flutter, which are increasingly guided by advanced mapping techniques, therefore most European countries will use these within regional collaboration frameworks.
   
• This promotes uniformity in clinical practice and increases the availability of sophisticated mapping systems needed in various facilities.
   

The Asia Pacific cardiac mapping market is anticipated to grow at the highest CAGR of 13.1% during the analysis timeframe.
 

• Cardiovascular diseases are on the rise in the Asia Pacific region due to factors such as urbanization, sedentary lifestyles, diabetes, and hypertension. Countries like China, Japan, India, Australia, Korea, and Taiwan are seeing a surge in atrial fibrillation and other arrhythmias among the elderly population. There is emerging need for diagnostic systems like cardiac mapping technologies.
   
• Furthermore, India, Thailand, and China are now leading regions for medical tourism because of their readily accessible affordable quality cardiac care. In Thailand alone, the medical tourism revenue experienced a growth of USD 2.7 billion in 2023, with cardiac procedures accounting for 15% of all visits from international patients.
   
• According to a report by the Ministry of Tourism, medical tourism market was valued at USD 6 billion in 2022 and expected to reach USD 13 billion by the end of 2026. Notably, Chinese hospitals experienced a surge of 45% international patients over the previous year.
   
• These countries have also incorporated advanced cardiac mapping systems for accurate ablation procedures to stay competitive. Such advancement is boosting the adoption of sophisticated cardiac technologies in the region.
   
• Additionally, educational professional bodies and international companies are hosting workshops, fellowships, and practical training throughout the Asia Pacific region. These activities are boosting the supply of trained electrophysiologists and building confidence within the region in the use of cardiac mapping technologies. Expanded education is playing a critical role in market growth.
   

The Latin America cardiac mapping market is experiencing robust growth over the analysis timeframe.
 

• Latin America’s growth is driven by the growing presence of regional cardiac specialty centers, increased participation in multinational clinical studies, and rising incidence of untreated and late-stage arrhythmias.
   
• Specialized cardiac centers and teaching hospitals in Brazil, Mexico, and Colombia are becoming major centers for electrophysiology procedures. According to the Brazilian Ministry of Health, the number of cardiac centers performing electrophysiology procedures increased by 28% between 2021 and 2023.
   
• Similarly, in Mexico, the National Institute of Cardiology reported a 35% rise in complex ablation procedures from 2022 to 2024. These facilities use advanced mapping systems for complex ablation procedures and provide training programs. These institutions help disseminate the best practices throughout the region.
   
• In addition, the rise of atrial fibrillation, particularly in countries such as Brazil, Mexico, and Argentina, is creating a need for sophisticated cardiac mapping technologies. As the Latin American region improves its healthcare infrastructure and invests in cardiology diagnostics and services, there is growing need for precise AFib detection and advanced treatment options that require real-time mapping systems.
   

Cardiac Mapping Market Share

The global market presents a moderately consolidated landscape, led by established medtech giants such as Johnson & Johnson (Biosense Webster), Abbott Laboratories, Boston Scientific Corporation, and Medtronic. These top players collectively accounting for approximately 97% of the total market share. These companies maintain a competitive edge through strong product portfolios, global commercial networks, and sustained investment in R&D.
 

Core market strategies include product launch, geographic expansion, regulatory approvals, partnerships, and acquisitions. For instance, in May 2024, Biosense Webster, a subsidiary of Johnson & Johnson MedTech, launched CARTO 3 System Version 8, the latest upgrade to its flagship 3D heart mapping platform. The new version delivers improved mapping accuracy and workflow efficiency, enabling more precise identification of arrhythmogenic tissue and enhancing ablation outcomes. This launches reinforced Biosense Webster’s technological leadership in the global cardiac mapping space.
 

Similarly, in July 2025, Boston Scientific received FDA approval for expanded labeling of its FARAPULSE Pulsed Field Ablation (PFA) System, allowing broader clinical use beyond paroxysmal atrial fibrillation. This regulatory milestone significantly bolstered FARAPULSE’s position in the U.S. market, facilitating wider adoption of PFA and accelerating the shift toward non-thermal ablation techniques in electrophysiology.
 

Meanwhile, early-stage innovation remains vibrant, with specialized firms like MicroPort Scientific, Lepu Medical, and Kardium developing high-density mapping catheters, real-time anatomical visualization tools, and integrated mapping-ablation systems. These companies often leverage partnerships or OEM arrangements to commercialize their technologies.
 

The market is further driven by rising demand for pulsed field ablation (PFA) systems and high-resolution 3D mapping, prompting both incumbents and new entrants to broaden their electrophysiology portfolios. As the global burden of atrial fibrillation and other complex arrhythmias continues to grow, there is a clear shift toward precision-guided, minimally invasive diagnostics. This evolution is fueling competition, with a strong emphasis on improving procedural accuracy, reducing operation times, and enhancing safety profiles, ultimately reshaping the competitive dynamics of the market.
 

Cardiac Mapping Market Companies

Few of the prominent players operating in the cardiac mapping industry include:
 

• Abbott Laboratories
• APN Health
• Boston Scientific
• EnChannel Medical
• Johnson & Johnson
• Kardium
• Lepu Medical
• Medtronic
• MicroPort Scientific

• Johnson & Johnson

Biosense Webster leads the market with its CARTO 3 System, offering high-resolution 3D electroanatomical mapping and advanced integration with ablation catheters. Its strong clinical evidence, widespread adoption, and continuous innovation in navigation technologies position it as the gold standard in complex arrhythmia procedures.
 

• Abbott Laboratories

Abbott stands out with its EnSite X EP System, featuring sensor-enabled mapping catheters that deliver flexible, high-density mapping with real-time anatomical and electrical insights. The platform's compatibility with robotic navigation (via its collaboration with Stereotaxis) enhances procedural precision and physician control.
 

• Boston Scientific

Boston Scientific distinguishes itself with the Rhythmia HDx Mapping System, which offers ultra-high-density mapping with rapid acquisition of detailed electroanatomical data. Its ability to generate over 100,000 data points automatically in a single procedure enables exceptional precision in identifying arrhythmogenic substrates, especially in complex or repeat ablations.
 

Cardiac Mapping Industry News:

• In July 2025, Johnson & Johnson MedTech announced the launch of the VARIPULSE Platform in Asia-Pacific. The platform is used to perform catheter ablation procedures for atrial fibrillation (AFib), an irregular and often rapid heartbeat caused by extra, uncoordinated electrical signals in the atria. This launch is expected to strengthen the company’s leadership in cardiac care by expanding its innovative product portfolio.
   
• In July 2025, Boston Scientific received FDA approval for the expanded labeling of its FARAPULSE Pulsed Field Ablation (PFA) System. This approval allows for broader clinical use, including treatment beyond paroxysmal atrial fibrillation. The regulatory milestone is expected to strengthen FARAPULSE’s position in the U.S. market, support wider adoption of PFA technology by physicians and accelerate the shift toward non-thermal ablation techniques in cardiac electrophysiology.
   
• In July 2025, EnChannel Medical Ltd. announced that it had signed a definitive agreement to acquire the AcQMap High-Resolution Imaging and Mapping platform assets from Acutus Medical Inc. The acquisition includes key intellectual property, regulatory and quality documentation, clinical data, as well as a limited number of AcQMap systems and associated catheters for research and development use. This strategic move is expected to strengthen EnChannel’s technological capabilities, expand its portfolio in high-resolution cardiac mapping, and enhance its competitiveness in the global electrophysiology and arrhythmia treatment market.
   
• In October 2024, Abbott announced that it had received U.S. Food and Drug Administration (FDA) clearance for its Advisor HD Grid X Mapping Catheter, Sensor Enabled. The catheter supports mapping in both pulsed field ablation (PFA) and radiofrequency (RF) ablation procedures, where precise visualization of cardiac anatomy is essential for optimal patient outcomes. This regulatory approval is expected to strengthen Abbott’s competitive position in the cardiac ablation market.
   

The cardiac mapping market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Mapping catheters
• Mapping systems

Market, By Type

• Contact cardiac mapping
• Non-contact cardiac mapping

Market, By Indiction

• Atrial fibrillation
• Atrial flutter
• Ventricular tachycardia
• Other indications

Market, By End Use

• Hospitals
• EP labs
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Netherlands
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE